Cite

    John M Pagel et al.. “Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.” Lancet oncology, vol. 23, no. 8, 2022, pp. 1021–1030. http://access.bl.uk/ark:/81055/vdc_100159754268.0x00001d